Valuation : NeurAxis, Inc.

Market Cap 72.96M 62.94M 59.2M 53.93M 101M 6.92B 102M 700M 272M 3.52B 274M 268M 11.68B P/E 2026 *
-5.33x
P/E 2027 * -21.5x
Enterprise Value 72.96M 62.94M 59.2M 53.93M 101M 6.92B 102M 700M 272M 3.52B 274M 268M 11.68B EV / Sales 2026 *
8.79x
EV / Sales 2027 * 3.68x
Free-Float
79.37%
Yield 2026 *
-
Yield 2027 * -
1 day-3.33%
1 week-3.81%
Current month-3.33%
1 month-7.04%
3 months-20.84%
6 months-3.17%
Current year+27.97%
1 week 5.72
Extreme 5.72
6.15
1 month 5.5
Extreme 5.5
7.21
Current year 4.12
Extreme 4.125
9.33
1 year 2.21
Extreme 2.21
9.33
3 years 1.33
Extreme 1.33
9.33
5 years 1.33
Extreme 1.33
9.33
10 years 1.33
Extreme 1.33
9.33
Manager TitleAgeSince
Corporate Officer/Principal 72 2010-12-31
Chief Executive Officer - 2010-12-31
Chief Executive Officer 44 2011-12-31
Director TitleAgeSince
Director/Board Member 44 2011-12-31
Director/Board Member 72 2010-12-31
Chairman 51 -
Date Insider Type Main position Quantity % Market Cap. Importance
8/24/26 Free

Compliance Officer

1,112,386 8.9153%
8/24/26 Free

Chief Technology Officer

1,210,718 9.7034%
8/24/26 Free

Chief Executive Officer

1,159,188 9.2904%
Change 5-day change 1-year change 3-year change Capi.($)
-3.33%-3.81%+128.74%+33.56% 72.96M
-0.16%-0.55%+18.32%+22.13% 12.71B
-0.29%-0.04%+16.03%+27.60% 6.91B
-4.16%-7.26%+38.81%+24.64% 6.29B
+10.66%+18.50% - - 6.3B
+1.85%-1.51%-18.27%+48.13% 5.17B
+0.65%-1.06%-31.11%-21.94% 3.88B
-1.53%-1.36%+40.96%-22.03% 2.02B
+0.83%+4.66%-2.25%+133.91% 1.79B
-2.19%-4.29%+48.57%-14.40% 1.63B
Average +0.23%+1.12%+26.64%+25.73% 4.68B
Weighted average by Cap. +0.93%+1.68%+13.34%+23.85%

Financials

2026 *2027 *
Net sales 8.3M 7.16M 6.73M 6.14M 11.54M 788M 11.6M 79.62M 30.99M 401M 31.16M 30.49M 1.33B 19.8M 17.08M 16.07M 14.64M 27.52M 1.88B 27.67M 190M 73.93M 956M 74.34M 72.73M 3.17B
Net income -12.9M -11.13M -10.47M -9.54M -17.93M -1.22B -18.03M -124M -48.16M -623M -48.43M -47.38M -2.06B -3.5M -3.02M -2.84M -2.59M -4.87M -332M -4.89M -33.57M -13.07M -169M -13.14M -12.86M -560M
Net Debt - -
Logo NeurAxis, Inc.
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension.
Employees
24
Date Price Change Volume
26-09-01 US$5.810 -3.33% 59,555
26-08-31 US$6.010 +0.17% 52,622
26-08-28 US$6.000 -0.33% 40,208
26-08-27 US$6.020 +1.01% 82,679
26-08-26 US$5.960 -1.32% 64,776
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.810USD
Average target price
11.00USD
Spread / Average Target
+89.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NRXS Stock